QT Imaging Q3 revenue jumps 75% on scanner sales

Overview

• U.S. breast imaging device maker's Q3 revenue rose 75% yr/yr to $7.3 mln

• Q3 net loss narrowed sharply to $0.3 mln from $4.6 mln a year ago

• 2026 revenue guidance cut to $34 mln due to Middle East shipment delays

Outlook

• QT Imaging lowers 2026 revenue guidance to approximately $34 mln from $39 mln

• Company says international shipment delays due to Middle East conflict impact 2026 outlook

• Medicare hospital outpatient payment for QTscan exams to begin Jan 1, 2027

Result Drivers

• SCANNER SALES - Q3 revenue growth driven by higher sales of Breast Acoustic CT scanners, per co

• MANUFACTURING EXPANSION - Co said relocation to new facility doubled manufacturing capacity and improved efficiency

• REIMBURSEMENT PROGRESS - CMS decision to establish Medicare hospital outpatient payment for QTscan exams seen as supporting future U.S. hospital expansion

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for QT Imaging Holdings Inc is $10.00, about 336.7% above its November 9 closing price of $2.29

Reuters Recommended Reads

• Nov 9 - Hyperfine Q3 revenue jumps on higher system sales; net loss narrows

• Nov 9 - Ocular Therapeutix Q3 loss widens as product revenue drops, costs rise

• Nov 10 - LENSAR Q3 revenue slightly misses estimates on slower surgical scheduling

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)